The synergic effects of PARP inhibitors with drug targeting of the ATR-CHK1 pathway on pediatric tumors was also observed by Southgate et al., who reported on the activity of the ATR inhibitor VE-821 and olaparib on four neuroblastoma cell lines [47], although a MYCN dependence was not clearly addressed in this study. This evidence concerns the gene CHEK1 and neuroblastoma.